Oxea, a global supplier of Oxo Intermediates and Oxo Derivatives, today announced for the fourth quarter of 2012 a strong earnings increase compared with the fourth quarter of 2011.
Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.
Newsletter & e-edition
News, trends and background information as well as the latest issue of CHEManager International